Also, in our experimental settings, pexidartinib was likely to block the IL34-driven alterations of the immune-vascular crosstalk, as CSF1 levels were unchanged in IL34-OE cancer cells and not associated with aggressiveness and progression of Renca tumors and metastases. Here, IL34 is linked to cancer.